For this purpose, re-setting target metabolomes based on new molecular classification of malignant gliomas (i.e., production of 2-hydroxyglutarate from IDH1 mutation) [34], and subsequent prospective CSF profiling study is necessary. The gene discussed is IDH1; the disease is malignant glioma.